Jackson Center, PA, January 12, 2021 – Halberd Corp. (OTC PINK: “HALB“) was recently included alongside Novavax Inc (NASDAQ:NVAX) and Moderna Inc (NASDAQ:MRNA) in a recent Wall Street PR article on Covid-19 related stocks poised to have an impact in 2021. Halberd was noted to be working in a different direction from the vaccine producers. According to the article, with vaccines already receiving pushback from the public, Halberd’s prevention and symptom alleviation approach, both pre-infection and post infection, may have a huge impact in the coming weeks and months.
Halberd’s two monoclonal antibodies against the SARS-Cov-2 spike protein, used together in a “cocktail” provide a potential way to prevent the virus from replicating and thus reducing the severity of the disease, if contracted. Equally important, it creates a mechanism to reduce or even eliminate the symptoms. The antibodies could also potentially be employed as a diagnostic tool.
Halberd’s Chief Technical Officer, Dr. Patricio Reyes, repeated his earlier comments, “This is very promising. In our in vitro experiments, our unique antibodies demonstrated a high degree of affinity and lysis for infected cells. We are now commencing in vivo studies to demonstrate their efficacy in diagnosing COVID-19 as well as preventing viral replication and multi-organ system damage associated with COVID-19. By eliminating the adverse consequences of contracting the virus, our quest is to make Covid irrelevant altogether.”
William A. Hartman, Chairman, President & CEO, reiterated, “We believe having multiple antibodies available not only increases our product application options, but also their effectiveness, when used in combination. While there is no definitive proof of efficacy yet, mathematically speaking, if each antibody is 90% effective independently, then, absent any interrelationship of the two applications, the combination should be 99% effective. In other words, the prospect of obtaining diagnostic test false positives or false negatives would be substantially reduced when antibodies work in tandem. The same would be true with regard to the use of antibodies in combination as a therapeutic tool as well as their use as a prophylactic measure in a preventative nasal spray. For this reason, we continue to move forward on the development and testing of the two antibodies which have survived the initial laboratory testing, and are now undergoing animal testing.”
In addition, continued Mr. Hartman, “Some of the research functions will likely be augmented through one or more additional research facilities. This multi-facility approach would only be undertaken to expedite the development of products and accelerate our time to market.
If you would like to be added to our email subscriber list, click here and submit the form.
About Halberd Corporation.
Halberd Corporation. (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd’s Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company’s Articles of Incorporation here.
The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus,” “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans,” “Nasal Spray to Prevent the Transmission of Covid-19,” and “Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus.” Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.